Skip to main content
. 2023 Feb 17;23:98. doi: 10.1186/s12879-023-08071-9

Table 3.

Patients characteristics associated with acceptance among PWH (N = 100)

Variable Would accept injections
(N = 74)
Would not accept injections
(N = 26)
P
Median age (IQR), years 50 (40–56) 52 (47–59) 0.18
Sex, n (%) 59 (80) 17 (65) 0.18
Mode of transmission, n (%) 0.072
 MSM 41 (55) 9 (35)
 Heterosexual 21 (28) 12 (46)
 Othera 12 (16) 5 (19)
Family life: single, n (%) 46 (62) 13 (50) 0.35
Has children, n (%) 29 (39) 13 (50) 0.36
Current worker, n (%) 56 (76) 15 (58) 0.13
Travels, n (%) 0.40
 1–2/year 34 (47) 14 (54)
  > 2/year 24 (33) 10 (38)
 Never 15 (21) 2 (8)
Current smokers, n (%) 15 (20) 7 (27) 0.58
Alcohol consumption: yes, n (%) 60 (81) 19 (73) 0.41
Drugs consumption: yes n (%) 16 (22) 4 (15) 0.58
IV drugs consumption: yes n (%) 7 (9) 1 (4) 0.68
CDC stage, n (%) 0.72
 C 11 (15) 4 (15)
Antiviral treatment duration, n (%) 0.24b
  < 1 year 5 (7) 0 (0)
 1–5 year 17 (23) 4 (15)
 5–10 year 10 (14) 6 (23)
  > 10 year 42 (57) 16 (62)
Antiviral treatment, n (%) 0.67
 Once a day 68 (92) 25 (96)
STR, n (%) 47 (64) 18 (69) 0.64
Median CD4 (IQR), cells/µl 746 (521–1002) 705 (528–805) 0.56
Median CD4 nadir (IQR), cells/µl 338 (185–446) 292 (150–439) 0.34
Hypertension, n (%) 18 (24) 7 (27) 0.80
Diabetes, n (%) 6 (8) 2 (8)  > 0.99
Hypercholesterolemia, n (%) 20 (27) 13 (50) 0.051
Psychiatric disorder, n (%) 13 (18) 2 (8) 0.34
Antidepressant, n (%) 8 (11) 1 (4) 0.44
Taking any non-HIV treatment, n (%) 34 (46) 11 (42) 0.82
Partner aware of treatment, n (%) 59 (80) 17 (65) 0.18
Family aware of treatment, n (%) 37 (50) 11 (42) 0.65
Friends aware of treatment, n (%) 39 (53) 8 (31) 0.069
Colleagues aware of treatment, n (%) 11 (15) 2 (8) 0.50
Never experienced AEs, n (%) 41 (55) 20 (80) 0.034
Never forgets treatment, n (%) 48 (65) 17 (65)  > 0.99

aOthers: mother to child, UIVD, unknown

bTrend test

P-values were obtained by Wilcoxon or Fisher’s exact tests